The Relationship of Retinol Binding Protein 4 to Changes in Insulin Resistance and Cardiometabolic Risk in Overweight Black Adolescents
To access this article, please choose from the options below
Supported by NIH grants HD41527, DK59183, DK43051, DK69624, and M01RR 08084. B.B.K. is the recipient of a research grant from Takeda Pharmaceutical Company, consultant to Wyeth and Boehringer Ingelheim and on the speakers' bureau for Merck. S.R.D. is a consultant to Abbott and Schering-Plough. B.B.K. and T.E.G. are inventors on patent applications related to RBP4.
PII: S0022-3476(08)00598-2
doi:10.1016/j.jpeds.2008.07.018
© 2009 Mosby, Inc. All rights reserved.
Refers to article:
- RBP4: From Retinol Transporter to Biomarker?
